Thursday, Dec 01, 2022

US PTO rules in Mylan’s favour, invalidates Teva patent: Natco

Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating Israel-based Teva Pharmaceuticals' patent related to multiple sclerosis drug Copaxone 40 mg/mL.

 

natco, natco pharmacy, natco US pto, natco mylan, mylan, mylan US pto, latest news, latest business news Natco Pharma said US PTO has ruled in favour of Mylan 

Drug firm Natco Pharma Friday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating Israel-based Teva Pharmaceuticals’ patent related to multiple sclerosis drug Copaxone 40 mg/mL.

“The US Patent and Trademark Office (PTO) has ruled in favour of its marketing partner, Mylan, in its inter partes review (IPR) proceeding and found all claims of US Patent No. 8,969,302, which is owned by Yeda Research and Development Co Ltd and licensed to Teva Pharmaceuticals Industries Ltd, unpatentable,” Natco Pharma said in a BSE filing.

Subscriber Only Stories
JK Cement’s SPSU Udaipur Launches ‘Golden Batch 2022’ In Collaboration Wi...Premium
Appendicitis in Children- A new lifestyle disorderPremium
Using evidence will create strong foundations for the future of education...Premium
Re-Defining The Tradition In Folk Art: An Art Educator’s PerspectivePremium

“This is the third patent related to Copaxone 40 mg/mL to be found unpatentable in the last week,” it further said.

Natco said its marketing partner Mylan believes it is one of the first companies to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/mL, and expects to be eligible for 180 days of marketing exclusivity in the US upon final FDA approval.

Quoting IMS Health data, the company said, Copaxone 40 mg/mL had US sales of approximately USD 3.3 billion for the 12 months ending June 30, 2016.

On August 24, the US Patent and Trademark Office (PTO) has ruled in favour of Mylan in its inter partes review (IPR) proceedings and found all claims of two related Copaxone 40 mg/mL patents to be unpatentable.

Advertisement

Shares of Natco Pharma were trading 0.01 per cent up at Rs 677 on BSE.

First published on: 02-09-2016 at 01:04:31 pm
Next Story

Arunachal Pradesh govt partners with BE Viacom18 to promote tourism in the state

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
close